- Meeting abstract
- Open Access
Small-animal PET evaluation of [11C]MC113 as a PET tracer for P-glycoprotein
© Langer et al; licensee BioMed Central Ltd. 2010
- Published: 16 November 2010
- Positron Emission Tomography
- Positron Emission Tomography Imaging
- Positron Emission Tomography Tracer
- Genetic Knockout
The radiolabelled inhibitor of the multidrug efflux transporter P-glycoprotein (P-gp) [11C]elacridar was developed as a positron emission tomography (PET) tracer to assess expression levels of P-gp at the blood-brain barrier (BBB) . [11C]Elacridar was shown to interact specifically with P-gp at the rodent BBB, but its brain PET signal was very low, which was possibly caused by transport of [11C]elacridar by P-gp . In an attempt to gain a better understanding of the required properties of an effective P-gp PET tracer we evaluated 11C-labelled MC113, a structural analogue of elacridar, which was characterised as an unambiguous non-transported P-gp inhibitor and which possesses lower molecular weight, lower lipophilicity and higher potency for P-gp inhibition than elacridar (EC50 for inhibition of [3H]vinblastine transport in Caco-2 cell monolayers: 0.6 µM vs. 2.0 µM for elacridar) .
Female wild-type (n = 3) and Mdr1a/b−/− (n = 2) mice (Taconic Inc., USA) underwent paired PET scans with [11C]MC113 using a microPET Focus220 scanner (Siemens, Medical Solutions, USA). A baseline scan (150 min), during which the P-gp inhibitor tariquidar (15 mg/kg) was administered i.v. at 60 min after radiotracer injection, was followed by a second 60-min scan at 2 h after administration of tariquidar. Whole-brain time-activity curves were calculated using the image analysis software Amide.
[11C]MC113 was evaluated using an identical set-up which we had previously used for [11C]elacridar and which employed a combination of chemical and genetic knockout of P-gp . [11C]MC113 had a 3 times higher peak brain activity uptake than [11C]elacridar, but otherwise behaved identically to [11C]elacridar, in that brain activity uptake was higher in Mdr1a/b−/− than in wild-type mice and that inhibitor administration increased brain activity uptake in wild-type mice. However, the observed effects were smaller for [11C]MC113 than for [11C]elacridar.
Our data suggest that [11C]MC113 interacts with P-gp at the murine blood-brain barrier, but as for [11C]elacridar its in vivo behaviour points to transport by P-gp. The higher brain activity uptake of [11C]MC113 might be an advantage over [11C]elacridar for PET imaging of P-gp.
The research leading to these results has received funding from the European Community’s 7th Framework Program under grant agreement no. 201380 (Euripides) and from the Austrian Science Fund (FWF) project ‘‘Transmembrane Transporters in Health and Disease’’ (SFB F35).
- Dörner B, Kuntner C, Bankstahl JP, Bankstahl M, Stanek J, Wanek T, Stundner G, Mairinger S, Löscher W, Müller M, Langer O, Erker T: Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J Med Chem. 2009, 52: 6073-6082. 10.1021/jm900940f.PubMed CentralView ArticlePubMedGoogle Scholar
- Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C, Niso M, Perrone R, Azzariti A, Simone GM, Paradiso A: 4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators. Bioorg Med Chem. 2008, 16: 3732-3743. 10.1016/j.bmc.2008.01.055.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd.